AccurKardia
Healthcare Software · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
101 6th Ave Ste 843, New York City, New ...Website
www.accurkardia.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
1
1
1
1
About AccurKardia
AccurKardia, Inc. specializes in leveraging AI technology to enhance the interpretation of ECG signals, transforming them into powerful diagnostic tools and biomarkers that improve patient outcomes. Their flagship product, AccurECG, is an FDA-cleared application that streamlines ECG interpretation for healthcare professionals. The company is also developing novel ECG applications, including AK-AVS and AK+ Guard, which are currently for research use only and not yet FDA approved. AccurKardia aims to extend the capabilities of ECGs beyond traditional uses, focusing on the detection and management of various health conditions.Explore more
AccurKardia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AccurKardia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if AccurKardia had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on AccurKardia recently announced quarterly report
Check out if AccurKardia is spiking on competitors!
Product Launch: Get notified when AccurKardia launches new products
AccurKardia, which may be a good buyer, showed buying intent in Masked Content Topic
Check if AccurKardia has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once AccurKardia has new funding data
Congratulate Masked Content for being promoted to Masked Content at AccurKardia
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined AccurKardia as Masked Content
Find more new buyers
Compare Similar Companies to AccurKardia
Compare insights from companies similar to AccurKardia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AccurKardia is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
AccurKardia is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about AccurKardia.
AccurKardia financials insights
Gather financial insights about AccurKardia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$2.7M
AccurKardia Tech Stack
A closer look at the technologies used by AccurKardia
Most Recent Scoops
Person-Based
Person-Based
Award
Award, Healthcare Technology
Person-Based
Person-Based
AccurKardia News & Media
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation
SANTA CLARA, Calif. & NEW YORK--(BUSINESS WIRE)--HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring InnovationAccurKardia Receives FDA Breakthrough Device Designation for AI-powered Hyperkalemia Detection Solution Using Lead I ECG Data
NEW YORK--(BUSINESS WIRE)-- #AI--AccurKardia, an innovator in ECG-based diagnostics technology, has announced that it has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its ECG-based, AI-powered AK+ Guard™ hyperkalemia detection software. The investigational technology uses Lead I ECG data to alert patients and clinicians of moderate to severe episodes of hyperkalemia (excess potassium in the blood) that can lead to sudden cardiac arrest. AK+ Guard isAccurKardia Receives FDA Breakthrough Device Designation for First-of-its-Kind Aortic Valve Stenosis ECG-based AI Screening Software
NEW YORK--(BUSINESS WIRE)-- #AorticStenosis--AccurKardia, an innovator in ECG-based diagnostics technology, has announced that its Aortic Valve Stenosis (AVS) ECG-based AI screening software has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The company’s AVS screening software aims to leverage the ubiquity of the electrocardiogram (ECG) to identify potential cases of AVS within millions of ECGs already present in healthcare system electronic health
Read more news
Top Healthcare Software Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AccurKardia
Sign Up For FreeTo access detailed company insights
AccurKardia, Inc. specializes in leveraging AI technology to enhance the interpretation of ECG signals, transforming them into powerful diagnostic tools and biomarkers that improve patient outcomes. Their flagship product, AccurECG, is an FDA-cleared application that streamlines ECG interpretation for healthcare professionals. The company is also d... Read More
